ES2686909B1 - Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas - Google Patents

Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas Download PDF

Info

Publication number
ES2686909B1
ES2686909B1 ES201730399A ES201730399A ES2686909B1 ES 2686909 B1 ES2686909 B1 ES 2686909B1 ES 201730399 A ES201730399 A ES 201730399A ES 201730399 A ES201730399 A ES 201730399A ES 2686909 B1 ES2686909 B1 ES 2686909B1
Authority
ES
Spain
Prior art keywords
cdc
treatment
inhibiting compounds
neurological pathologies
pathologies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201730399A
Other languages
English (en)
Other versions
ES2686909A1 (es
Inventor
Gil Ana Martinez
Daniel I Perez
Ayuso-Gontan Carmen Gil
Angeles Martin-Requero
Prats Elisa Rojas
Loreto Martinez-Gonzalez
Concepcion Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201730399A priority Critical patent/ES2686909B1/es
Priority to US16/495,613 priority patent/US11446304B2/en
Priority to AU2018240527A priority patent/AU2018240527B2/en
Priority to PCT/ES2018/070215 priority patent/WO2018172587A1/es
Priority to EP18771997.6A priority patent/EP3604310A4/en
Publication of ES2686909A1 publication Critical patent/ES2686909A1/es
Application granted granted Critical
Publication of ES2686909B1 publication Critical patent/ES2686909B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201730399A 2017-03-22 2017-03-22 Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas Active ES2686909B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201730399A ES2686909B1 (es) 2017-03-22 2017-03-22 Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas
US16/495,613 US11446304B2 (en) 2017-03-22 2018-03-21 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions
AU2018240527A AU2018240527B2 (en) 2017-03-22 2018-03-21 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions
PCT/ES2018/070215 WO2018172587A1 (es) 2017-03-22 2018-03-21 Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologías neurológicas
EP18771997.6A EP3604310A4 (en) 2017-03-22 2018-03-21 CDC-7 INHIBITOR COMPOUNDS AND USE THEREOF IN THE TREATMENT OF NEUROLOGICAL DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201730399A ES2686909B1 (es) 2017-03-22 2017-03-22 Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas

Publications (2)

Publication Number Publication Date
ES2686909A1 ES2686909A1 (es) 2018-10-22
ES2686909B1 true ES2686909B1 (es) 2019-08-16

Family

ID=63584204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201730399A Active ES2686909B1 (es) 2017-03-22 2017-03-22 Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas

Country Status (5)

Country Link
US (1) US11446304B2 (es)
EP (1) EP3604310A4 (es)
AU (1) AU2018240527B2 (es)
ES (1) ES2686909B1 (es)
WO (1) WO2018172587A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2749743B2 (es) * 2018-09-21 2020-12-14 Consejo Superior Investigacion Derivados de purina inhibidores de cdc7 y su uso para el tratamiento de patologias neurologicas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232937A (en) * 1962-08-02 1966-02-01 Burroughs Wellcome Co 6-benzylmercaptopurines
EA000072B1 (ru) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
JP2004161716A (ja) * 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
KR20080110912A (ko) 2006-04-19 2008-12-19 노파르티스 아게 인다졸 화합물 및 ｃｄｃ７의 억제 방법
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
CA2767091A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions

Also Published As

Publication number Publication date
AU2018240527A1 (en) 2019-11-07
US20200093828A1 (en) 2020-03-26
ES2686909A1 (es) 2018-10-22
AU2018240527B2 (en) 2022-05-19
EP3604310A4 (en) 2020-09-02
WO2018172587A1 (es) 2018-09-27
EP3604310A1 (en) 2020-02-05
US11446304B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL274534A (en) Processes for the separation of benzodiazepine-2-ones and benzodiazepine-2-one derivatives
BR112016022598A2 (pt) Formulação de rapamicina inalável para o tratamento de condições relacionadas com a idade
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
IL277749A (en) Palladianolide compounds and their use
ES1178860Y (es) Atuendo para facilitar la utilizacion de piedras para chakras
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
ES2686909B1 (es) Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas
EP3638219C0 (en) COMPOSITION CONTAINING TERPINEN-4-OL FOR THE TREATMENT OF DEMODICOSE
HUE051989T2 (hu) Berendezés szerves anyagok kezelésére
ES1222400Y (es) Dispositivo para el tratamiento de enfermedades degenerativas
ES1219729Y (es) Biovelo para el tratamiento de heridas y quemaduras
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
ES1218143Y (es) Fresa para el tratamiento de la perimplantitis
ES1229528Y (es) Aparato para el tratamiento de ciatica, lumbociatica y epicondilitis
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
ES1165233Y (es) Dispositivo para el tratamiento de olores desagradables
ES1182359Y (es) Aparato para la preparación de infusiones
ES1201887Y (es) Dispositivo para tratamiento del suelo pelvico
IT201700054488A1 (it) Composizione per il trattamento di forme infiammatorie cutanee

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2686909

Country of ref document: ES

Kind code of ref document: A1

Effective date: 20181022

FG2A Definitive protection

Ref document number: 2686909

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20190816